Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 206

1.

Use of biologically-based complementary medicine in breast and gynecological cancer patients during systemic therapy.

Drozdoff L, Klein E, Kiechle M, Paepke D.

BMC Complement Altern Med. 2018 Sep 24;18(1):259. doi: 10.1186/s12906-018-2325-3.

2.

Model-based learning of local image features for unsupervised texture segmentation.

Kiechle M, Storath M, Weinmann A, Kleinsteuber M.

IEEE Trans Image Process. 2018 Jan 12. doi: 10.1109/TIP.2018.2792904. [Epub ahead of print]

PMID:
29994498
3.

Demand for integrative medicine among women in pregnancy and childbed: a German survey on patients' needs.

Schürger N, Klein E, Hapfelmeier A, Kiechle M, Paepke D.

BMC Complement Altern Med. 2018 Jun 15;18(1):187. doi: 10.1186/s12906-018-2249-y.

4.

Modifiable Lifestyle Factors: Opportunities for (Hereditary) Breast Cancer Prevention - a Narrative Review.

Lammert J, Grill S, Kiechle M.

Breast Care (Basel). 2018 Apr;13(2):109-114. doi: 10.1159/000488995. Epub 2018 Apr 20. Review.

PMID:
29887787
5.

Mammography Screening 2.0 - How Can Risk-Adapted Screening be Implemented in Clinical Practice?: Results of a Focus Group Discussion with Experts in the RISIKOLOTSE.DE Project.

Fürst N, Kiechle M, Strahwald B, Quante AS.

Geburtshilfe Frauenheilkd. 2018 May;78(5):506-511. doi: 10.1055/a-0603-4314. Epub 2018 Jun 4.

6.

Costs and effects of intra-operative fluorescence molecular imaging - A model-based, early assessment.

Präger M, Kiechle M, Stollenwerk B, Hinzen C, Glatz J, Vogl M, Leidl R.

PLoS One. 2018 Jun 1;13(6):e0198137. doi: 10.1371/journal.pone.0198137. eCollection 2018.

7.

Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix.

Jesinghaus M, Strehl J, Boxberg M, Brühl F, Wenzel A, Konukiewitz B, Schlitter AM, Steiger K, Warth A, Schnelzer A, Kiechle M, Beckmann MW, Noske A, Hartmann A, Mehlhorn G, Koch MC, Weichert W.

J Pathol Clin Res. 2018 Apr;4(2):93-102. doi: 10.1002/cjp2.95. Epub 2018 Mar 8.

8.

Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.

Dettmar L, Ahmed N, Kotzsch M, Diersch S, Napieralski R, Darmoul D, Schmitt M, Weichert W, Kiechle M, Dorn J, Magdolen V.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1109-1118. doi: 10.1007/s00432-018-2623-7. Epub 2018 Mar 15.

PMID:
29546479
9.

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.

Engel C, Rhiem K, Hahnen E, Loibl S, Weber KE, Seiler S, Zachariae S, Hauke J, Wappenschmidt B, Waha A, Blümcke B, Kiechle M, Meindl A, Niederacher D, Bartram CR, Speiser D, Schlegelberger B, Arnold N, Wieacker P, Leinert E, Gehrig A, Briest S, Kast K, Riess O, Emons G, Weber BHF, Engel J, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).

BMC Cancer. 2018 Mar 7;18(1):265. doi: 10.1186/s12885-018-4029-y.

10.

The Association between Serum 25-Hydroxyvitamin D and Cancer Risk: Results from the Prospective KORA F4 Study.

Cheney CP, Thorand B, Huth C, Berger K, Peters A, Seifert-Klauss V, Kiechle M, Strauch K, Quante AS.

Oncol Res Treat. 2018;41(3):117-121. doi: 10.1159/000485512. Epub 2018 Feb 27.

PMID:
29485414
11.

Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Lammert J, Lubinski J, Gronwald J, Huzarski T, Armel S, Eisen A, Meschino WS, Lynch HT, Snyder C, Eng C, Olopade OI, Ginsburg O, Foulkes WD, Elser C, Cohen SA, Kiechle M, Narod SA, Kotsopoulos J.

Breast Cancer Res Treat. 2018 Jun;169(3):561-571. doi: 10.1007/s10549-018-4694-1. Epub 2018 Feb 5.

PMID:
29404807
12.

PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.

Absmaier M, Napieralski R, Schuster T, Aubele M, Walch A, Magdolen V, Dorn J, Gross E, Harbeck N, Noske A, Kiechle M, Schmitt M.

Int J Oncol. 2018 Mar;52(3):755-767. doi: 10.3892/ijo.2018.4241. Epub 2018 Jan 8.

13.

Age-dependent differences in DNA damage after in vitro CT exposure.

Gomolka M, Oestreicher U, Rößler U, Samaga D, Endesfelder D, Lang P, Neumaier K, Belka C, Niemeyer M, Kiechle M, Hasbargen U, Hübener C, Kirlum HJ, Kulka U, Rosenberger A, Walsh L, Baatout S, Kesminiene A, Lindholm C.

Int J Radiat Biol. 2018 Mar;94(3):272-281. doi: 10.1080/09553002.2018.1419302. Epub 2018 Jan 25.

PMID:
29319401
14.

The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges.

Aubele M, Schmitt M, Napieralski R, Paepke S, Ettl J, Absmaier M, Magdolen V, Martens J, Foekens JA, Wilhelm OG, Kiechle M.

Dis Markers. 2017;2017:4934608. doi: 10.1155/2017/4934608. Epub 2017 Sep 12. Review.

15.

Knee arthrodesis versus above-the-knee amputation after septic failure of revision total knee arthroplasty: comparison of functional outcome and complication rates.

Hungerer S, Kiechle M, von Rüden C, Militz M, Beitzel K, Morgenstern M.

BMC Musculoskelet Disord. 2017 Nov 13;18(1):443. doi: 10.1186/s12891-017-1806-8.

16.

Feasibility of structured endurance training and Mediterranean diet in BRCA1 and BRCA2 mutation carriers - an interventional randomized controlled multicenter trial (LIBRE-1).

Kiechle M, Dukatz R, Yahiaoui-Doktor M, Berling A, Basrai M, Staiger V, Niederberger U, Marter N, Lammert J, Grill S, Pfeifer K, Rhiem K, Schmutzler RK, Laudes M, Siniatchkin M, Halle M, Bischoff SC, Engel C.

BMC Cancer. 2017 Nov 10;17(1):752. doi: 10.1186/s12885-017-3732-4.

17.

Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.

Geng X, Liu Y, Diersch S, Kotzsch M, Grill S, Weichert W, Kiechle M, Magdolen V, Dorn J.

PLoS One. 2017 Nov 2;12(11):e0186847. doi: 10.1371/journal.pone.0186847. eCollection 2017.

18.

Smoking and physical inactivity increase cancer prevalence in BRCA-1 and BRCA-2 mutation carriers: results from a retrospective observational analysis.

Grill S, Yahiaoui-Doktor M, Dukatz R, Lammert J, Ullrich M, Engel C, Pfeifer K, Basrai M, Siniatchkin M, Schmidt T, Weisser B, Rhiem K, Ditsch N, Schmutzler R, Bischoff SC, Halle M, Kiechle M.

Arch Gynecol Obstet. 2017 Dec;296(6):1135-1144. doi: 10.1007/s00404-017-4546-y. Epub 2017 Oct 3.

PMID:
28975393
19.

Time trends (2006-2015) of quality indicators in EUSOMA-certified breast centres.

van Dam PA, Tomatis M, Marotti L, Heil J, Mansel RE, Rosselli Del Turco M, van Dam PJ, Casella D, Bassani LG, Danei M, Denk A, Egle D, Emons G, Friedrichs K, Harbeck N, Kiechle M, Kimmig R, Koehler U, Kuemmel S, Maass N, Mayr C, Prové A, Rageth C, Regolo L, Lorenz-Salehi F, Sarlos D, Singer C, Sohn C, Staelens G, Tinterri C, Audisio R, Ponti A; eusomaDB Working Group.

Eur J Cancer. 2017 Nov;85:15-22. doi: 10.1016/j.ejca.2017.07.040. Epub 2017 Sep 4.

PMID:
28881247
20.

Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.

Ettl J, Klein E, Hapfelmeier A, Grosse Lackmann K, Paepke S, Petry C, Specht K, Wolff L, Höfler H, Kiechle M.

PLoS One. 2017 Sep 6;12(9):e0183917. doi: 10.1371/journal.pone.0183917. eCollection 2017.

21.

Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer.

Yang F, Aubele M, Walch A, Gross E, Napieralski R, Zhao S, Ahmed N, Kiechle M, Reuning U, Dorn J, Sweep F, Magdolen V, Schmitt M.

Biol Chem. 2017 Sep 26;398(10):1151-1164. doi: 10.1515/hsz-2017-0122.

PMID:
28755528
22.

The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (α-syn) oligomerization and secretion.

von Einem B, Eschbach J, Kiechle M, Wahler A, Thal DR, McLean PJ, Weishaupt JH, Ludolph AC, von Arnim CAF, Danzer KM.

Aging (Albany NY). 2017 Jul 15;9(7):1677-1697. doi: 10.18632/aging.101261.

23.

Mobile Health in Oncology: A Patient Survey About App-Assisted Cancer Care.

Kessel KA, Vogel MM, Kessel C, Bier H, Biedermann T, Friess H, Herschbach P, von Eisenhart-Rothe R, Meyer B, Kiechle M, Keller U, Peschel C, Schmid RM, Combs SE.

JMIR Mhealth Uhealth. 2017 Jun 14;5(6):e81. doi: 10.2196/mhealth.7689.

24.

Induction of cathepsin B by the CXCR3 chemokines CXCL9 and CXCL10 in human breast cancer cells.

Bronger H, Karge A, Dreyer T, Zech D, Kraeft S, Avril S, Kiechle M, Schmitt M.

Oncol Lett. 2017 Jun;13(6):4224-4230. doi: 10.3892/ol.2017.5994. Epub 2017 Apr 5.

25.

Gynecologic oncologists' attitudes and practices relating to integrative medicine: results of a nationwide AGO survey.

Klein E, Beckmann MW, Bader W, Brucker C, Dobos G, Fischer D, Hanf V, Hasenburg A, Jud SM, Kalder M, Kiechle M, Kümmel S, Müller A, Müller MT, Paepke D, Rotmann AR, Schütz F, Scharl A, Voiss P, Wallwiener M, Witt C, Hack CC.

Arch Gynecol Obstet. 2017 Aug;296(2):295-301. doi: 10.1007/s00404-017-4420-y. Epub 2017 Jun 8.

26.

Validation of the German version of the Mediterranean Diet Adherence Screener (MEDAS) questionnaire.

Hebestreit K, Yahiaoui-Doktor M, Engel C, Vetter W, Siniatchkin M, Erickson N, Halle M, Kiechle M, Bischoff SC.

BMC Cancer. 2017 May 18;17(1):341. doi: 10.1186/s12885-017-3337-y.

27.

CXCR3 mediates ascites-directed tumor cell migration and predicts poor outcome in ovarian cancer patients.

Windmüller C, Zech D, Avril S, Boxberg M, Dawidek T, Schmalfeldt B, Schmitt M, Kiechle M, Bronger H.

Oncogenesis. 2017 May 15;6(5):e331. doi: 10.1038/oncsis.2017.29.

28.

Cancer of the ovary, fallopian tube, and peritoneum: a population-based comparison of the prognostic factors and outcomes.

Rottmann M, Burges A, Mahner S, Anthuber C, Beck T, Grab D, Schnelzer A, Kiechle M, Mayr D, Pölcher M, Schubert-Fritschle G, Engel J.

J Cancer Res Clin Oncol. 2017 Sep;143(9):1833-1844. doi: 10.1007/s00432-017-2422-6. Epub 2017 Apr 26.

PMID:
28447160
29.

Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry.

Hölzel D, Eckel R, Bauerfeind I, Baier B, Beck T, Braun M, Ettl J, Hamann U, Kiechle M, Mahner S, Schindlbeck C, de Waal J, Harbeck N, Engel J.

J Cancer Res Clin Oncol. 2017 Sep;143(9):1701-1712. doi: 10.1007/s00432-017-2428-0. Epub 2017 Apr 20.

PMID:
28429102
30.

Mammographic Density and Vitamin D Levels - A Cross-sectional Study.

Straub L, Riedel J, Luppa PB, Wissing J, Artmann A, Kiechle M, Seifert-Klauss VR.

Geburtshilfe Frauenheilkd. 2017 Mar;77(3):257-267. doi: 10.1055/s-0043-102694.

31.

C-Peptide, Baseline and Postprandial Insulin Resistance after a Carbohydrate-Rich Test Meal - Evidence for an Increased Insulin Clearance in PCOS Patients?

Stassek J, Erdmann J, Ohnolz F, Berg FD, Kiechle M, Seifert-Klauss V.

Geburtshilfe Frauenheilkd. 2017 Jan;77(1):59-65. doi: 10.1055/s-0042-119199.

32.

MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.

Raychaudhuri M, Bronger H, Buchner T, Kiechle M, Weichert W, Avril S.

Breast Cancer Res Treat. 2017 Apr;162(3):511-521. doi: 10.1007/s10549-017-4132-9. Epub 2017 Feb 8.

33.

Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study).

Kiechle M, Engel C, Berling A, Hebestreit K, Bischoff S, Dukatz R, Gerber WD, Siniatchkin M, Pfeifer K, Grill S, Yahiaoui-Doktor M, Kirsch E, Niederberger U, Marter N, Enders U, Löffler M, Meindl A, Rhiem K, Schmutzler R, Erickson N, Halle M.

Pilot Feasibility Stud. 2016 Dec 19;2:74. doi: 10.1186/s40814-016-0114-7. eCollection 2016.

34.

Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.

Zhao S, Dorn J, Napieralski R, Walch A, Diersch S, Kotzsch M, Ahmed N, Hooper JD, Kiechle M, Schmitt M, Magdolen V.

Biol Chem. 2017 Jun 27;398(7):765-773. doi: 10.1515/hsz-2016-0282.

PMID:
27935848
35.

Experience with oral emergency contraception since the OTC switch in Germany.

Kiechle M, Neuenfeldt M.

Arch Gynecol Obstet. 2017 Mar;295(3):651-660. doi: 10.1007/s00404-016-4253-0. Epub 2016 Nov 28.

36.

The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.

Leinert E, Singer S, Janni W, Harbeck N, Weissenbacher T, Rack B, Augustin D, Wischnik A, Kiechle M, Ettl J, Fink V, Schwentner L, Eichler M.

Clin Breast Cancer. 2017 Apr;17(2):100-106. doi: 10.1016/j.clbc.2016.10.008. Epub 2016 Oct 19.

PMID:
27884722
37.

Sarcopenia in Advanced Serous Ovarian Cancer.

Bronger H, Hederich P, Hapfelmeier A, Metz S, Noël PB, Kiechle M, Schmalfeldt B.

Int J Gynecol Cancer. 2017 Feb;27(2):223-232. doi: 10.1097/IGC.0000000000000867.

PMID:
27870708
38.

Survival of de novo stage IV breast cancer patients over three decades.

Hölzel D, Eckel R, Bauerfeind I, Baier B, Beck T, Braun M, Ettl J, Hamann U, Harbeck N, Kiechle M, Mahner S, Schindlbeck C, de Waal J, Engel J.

J Cancer Res Clin Oncol. 2017 Mar;143(3):509-519. doi: 10.1007/s00432-016-2306-1. Epub 2016 Nov 16.

PMID:
27853869
39.

Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.

Gross E, van Tinteren H, Li Z, Raab S, Meul C, Avril S, Laddach N, Aubele M, Propping C, Gkazepis A, Schmitt M, Meindl A, Nederlof PM, Kiechle M, Lips EH.

BMC Cancer. 2016 Oct 19;16(1):811.

40.

Trends in use and outcome of postoperative radiotherapy following mastectomy: A population-based study.

Corradini S, Bauerfeind I, Belka C, Braun M, Combs SE, Eckel R, Harbeck N, Hölzel D, Kiechle M, Niyazi M, Engel J.

Radiother Oncol. 2017 Jan;122(1):2-10. doi: 10.1016/j.radonc.2016.08.018. Epub 2016 Sep 15.

PMID:
27641786
41.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W.

Ann Oncol. 2017 Nov 1;28(11):2899. doi: 10.1093/annonc/mdw349. No abstract available.

PMID:
27634692
42.

CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.

Bronger H, Singer J, Windmüller C, Reuning U, Zech D, Delbridge C, Dorn J, Kiechle M, Schmalfeldt B, Schmitt M, Avril S.

Br J Cancer. 2016 Aug 23;115(5):553-63. doi: 10.1038/bjc.2016.172. Epub 2016 Aug 4.

43.

Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer.

Ahmed N, Dorn J, Napieralski R, Drecoll E, Kotzsch M, Goettig P, Zein E, Avril S, Kiechle M, Diamandis EP, Schmitt M, Magdolen V.

Biol Chem. 2016 Dec 1;397(12):1265-1276. doi: 10.1515/hsz-2016-0177.

44.

Effects of lifestyle intervention in BRCA1/2 mutation carriers on nutrition, BMI, and physical fitness (LIBRE study): study protocol for a randomized controlled trial.

Kiechle M, Engel C, Berling A, Hebestreit K, Bischoff SC, Dukatz R, Siniatchkin M, Pfeifer K, Grill S, Yahiaoui-Doktor M, Kirsch E, Niederberger U, Enders U, Löffler M, Meindl A, Rhiem K, Schmutzler R, Erickson N, Halle M.

Trials. 2016 Jul 29;17:368. doi: 10.1186/s13063-016-1504-0.

45.

Concordance rates of biomarkers uPA and PAI-1 results in primary breast cancer vs. consecutive tumor board decision and therapy performed in clinical hospital routine: Results of a prospective multi-center study at certified breast centers.

Jacobs VR, Augustin D, Wischnik A, Kiechle M, Hoess C, Steinkohl O, Rack B, Kapitza T, Krase P.

Breast. 2016 Oct;29:208-12. doi: 10.1016/j.breast.2016.06.014. Epub 2016 Jun 23.

PMID:
27344290
46.

Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial.

Eichler M, Singer S, Janni W, Harbeck N, Rack B, Augustin D, Wischnik A, Kiechle M, Ettl J, Scholz C, Fink V, Schwentner L.

Breast Cancer. 2017 Mar;24(2):319-325. doi: 10.1007/s12282-016-0706-3. Epub 2016 Jun 4.

PMID:
27262301
47.

Vitamin D and Mammographic Findings.

Riedel J, Straub L, Wissing J, Artmann A, Schmidmayr M, Kiechle M, Seifert-Klauss VR.

Geburtshilfe Frauenheilkd. 2016 May;76(5):570-578.

48.

Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome.

Dorn J, Yassouridis A, Walch A, Diamandis EP, Schmitt M, Kiechle M, Wang P, Drecoll E, Schmalfeldt B, Loessner D, Kotzsch M, Magdolen V.

Am J Cancer Res. 2015 Dec 15;6(1):61-70. eCollection 2016.

49.

Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial.

Schwentner L, Harbeck N, Singer S, Eichler M, Rack B, Forstbauer H, Wischnik A, Scholz C, Huober J, Friedl TW, Weissenbacher T, Härtl K, Kiechle M, Janni W, Fink V.

Breast. 2016 Jun;27:69-77. doi: 10.1016/j.breast.2016.03.003. Epub 2016 Apr 4.

PMID:
27054751
50.

Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.

Janni W, Harbeck N, Rack B, Augustin D, Jueckstock J, Wischnik A, Annecke K, Scholz C, Huober J, Zwingers T, Friedl TW, Kiechle M.

Br J Cancer. 2016 Apr 12;114(8):863-71. doi: 10.1038/bjc.2016.82. Epub 2016 Mar 31.

Supplemental Content

Loading ...
Support Center